The Experts below are selected from a list of 18 Experts worldwide ranked by ideXlab platform
Carol L Szumlanski - One of the best experts on this subject based on the ideXlab platform.
-
methylation Pharmacogenetics catechol o methyltransferase thiopurine methyltransferase and histamine n methyltransferase
Annual Review of Pharmacology and Toxicology, 1999Co-Authors: Richard M Weinshilboum, Diane M. Otterness, Carol L SzumlanskiAbstract:▪ Abstract Methyl conjugation is an important pathway in the biotransformation of many exogenous and endogenous compounds. Pharmacogenetic studies of methyltransferase enzymes have resulted in the identification and characterization of functionally important common genetic polymorphisms for catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. In recent years, characterization of these genetic polymorphisms has been extended to include the cloning of cDNAs and genes, as well as a determination of the molecular basis for the effects of inheritance on these methyltransferase enzymes. The thiopurine methyltransferase genetic polymorphism is responsible for clinically significant individual variations in the toxicity and therapeutic efficacy of thiopurine drugs such as 6-mercaptopurine. Phenotyping for the thiopurine methyltransferase genetic polymorphism represents one of the first examples in which testing for a Pharmacogenetic Variant has entered standard clinical p...
Richard M Weinshilboum - One of the best experts on this subject based on the ideXlab platform.
-
methylation Pharmacogenetics catechol o methyltransferase thiopurine methyltransferase and histamine n methyltransferase
Annual Review of Pharmacology and Toxicology, 1999Co-Authors: Richard M Weinshilboum, Diane M. Otterness, Carol L SzumlanskiAbstract:▪ Abstract Methyl conjugation is an important pathway in the biotransformation of many exogenous and endogenous compounds. Pharmacogenetic studies of methyltransferase enzymes have resulted in the identification and characterization of functionally important common genetic polymorphisms for catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. In recent years, characterization of these genetic polymorphisms has been extended to include the cloning of cDNAs and genes, as well as a determination of the molecular basis for the effects of inheritance on these methyltransferase enzymes. The thiopurine methyltransferase genetic polymorphism is responsible for clinically significant individual variations in the toxicity and therapeutic efficacy of thiopurine drugs such as 6-mercaptopurine. Phenotyping for the thiopurine methyltransferase genetic polymorphism represents one of the first examples in which testing for a Pharmacogenetic Variant has entered standard clinical p...
Diane M. Otterness - One of the best experts on this subject based on the ideXlab platform.
-
methylation Pharmacogenetics catechol o methyltransferase thiopurine methyltransferase and histamine n methyltransferase
Annual Review of Pharmacology and Toxicology, 1999Co-Authors: Richard M Weinshilboum, Diane M. Otterness, Carol L SzumlanskiAbstract:▪ Abstract Methyl conjugation is an important pathway in the biotransformation of many exogenous and endogenous compounds. Pharmacogenetic studies of methyltransferase enzymes have resulted in the identification and characterization of functionally important common genetic polymorphisms for catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. In recent years, characterization of these genetic polymorphisms has been extended to include the cloning of cDNAs and genes, as well as a determination of the molecular basis for the effects of inheritance on these methyltransferase enzymes. The thiopurine methyltransferase genetic polymorphism is responsible for clinically significant individual variations in the toxicity and therapeutic efficacy of thiopurine drugs such as 6-mercaptopurine. Phenotyping for the thiopurine methyltransferase genetic polymorphism represents one of the first examples in which testing for a Pharmacogenetic Variant has entered standard clinical p...
R Soong - One of the best experts on this subject based on the ideXlab platform.
-
Can population differences in chemotherapy outcomes be inferred from differences in Pharmacogenetic frequencies?
The Pharmacogenomics Journal, 2013Co-Authors: D Chua, K Garrett, N Zeps, C Platell, T Minamoto, K Kawakami, B Iacopetta, R SoongAbstract:Inter-ethnic differences in drug handling and frequencies of Pharmacogenetic Variants are increasingly being characterized. In this study, we systematically assessed the feasibility of inferring ethnic trends in chemotherapy outcomes from inter-ethnic differences in Pharmacogenetic Variant frequencies. Frequencies of 51 Variants and chemotherapy outcomes of East Asian and Caucasian colorectal cancer patients on standard chemotherapy regimens were summarized by meta-analyses, and Variant frequencies were validated by MassARRAY analysis. Inferences of relative chemotherapy outcomes were made by considering minor allele function and population differences in their frequency. Significant population differences in genotype distributions were observed for 13/23 (60%) and 27/35 (77%) Variants in the meta-analyses and validation series, respectively. Across chemotherapy regimens, East Asians had lower rates of grade 3/4 toxicity for diarrhea and stomatitis/mucositis than Caucasians, which was correctly inferred from 13/18 (72%, P =0.018) informative genetic Variants. With appropriate Variant selection, inferring relative population toxicity rates from population genotype differences may be relevant.
D Chua - One of the best experts on this subject based on the ideXlab platform.
-
Can population differences in chemotherapy outcomes be inferred from differences in Pharmacogenetic frequencies?
The Pharmacogenomics Journal, 2013Co-Authors: D Chua, K Garrett, N Zeps, C Platell, T Minamoto, K Kawakami, B Iacopetta, R SoongAbstract:Inter-ethnic differences in drug handling and frequencies of Pharmacogenetic Variants are increasingly being characterized. In this study, we systematically assessed the feasibility of inferring ethnic trends in chemotherapy outcomes from inter-ethnic differences in Pharmacogenetic Variant frequencies. Frequencies of 51 Variants and chemotherapy outcomes of East Asian and Caucasian colorectal cancer patients on standard chemotherapy regimens were summarized by meta-analyses, and Variant frequencies were validated by MassARRAY analysis. Inferences of relative chemotherapy outcomes were made by considering minor allele function and population differences in their frequency. Significant population differences in genotype distributions were observed for 13/23 (60%) and 27/35 (77%) Variants in the meta-analyses and validation series, respectively. Across chemotherapy regimens, East Asians had lower rates of grade 3/4 toxicity for diarrhea and stomatitis/mucositis than Caucasians, which was correctly inferred from 13/18 (72%, P =0.018) informative genetic Variants. With appropriate Variant selection, inferring relative population toxicity rates from population genotype differences may be relevant.